ATI PN PHARMACOLOGY LEVEL 3 PROCTORED EXAM
2026/2027 370 Q&As WITH NGN & RATIONALES
Practical Nursing Pharmacology Verified | 2026/2027 ATI PN
Pharmacology Curriculum Next Generation NCLEX-PN (NGN)
Standards
Domain: Pharmacokinetics & Pharmacodynamics
Q1. A patient takes an oral medication that undergoes extensive first-pass
metabolism. Which route of administration would bypass the first-pass effect
and increase bioavailability?
○ A. Sublingual
○ B. Oral sustained-release
○ C. Rectal suppository
○ D. Enteric-coated oral
CORRECT ANSWER: A. Sublingual
RATIONALE: The first-pass effect occurs when a drug is absorbed from the GI tract
and passes through the liver before reaching systemic circulation, significantly
reducing bioavailability. Sublingual administration allows the drug to be absorbed
directly into the systemic circulation through the rich vascular supply under the
tongue, completely bypassing hepatic first-pass metabolism. This results in higher
bioavailability compared to oral routes for drugs that undergo extensive first-pass
metabolism. Oral sustained-release formulations still pass through the liver via the
portal circulation and are subject to first-pass metabolism. Rectal suppositories
partially bypass the first-pass effect but a significant portion of the drug still drains
into the portal circulation via the inferior and middle hemorrhoidal veins. Enteric-
coated oral medications are designed to dissolve in the intestine but still undergo
first-pass metabolism once absorbed.
Q2. A patient with liver cirrhosis is prescribed a medication that is highly
protein-bound. Which pharmacokinetic change should the PN anticipate?
,○ A. Decreased drug half-life
○ B. Increased free drug concentration
○ C. Decreased drug absorption
○ D. Increased drug excretion
CORRECT ANSWER: B. Increased free drug concentration
RATIONALE: Liver cirrhosis reduces albumin production, leading to decreased
protein-binding capacity. With fewer protein-binding sites available, a greater
fraction of the drug remains unbound (free) in the circulation. The free fraction is
pharmacologically active and can lead to increased therapeutic effects or toxicity.
Decreased drug half-life would occur with enhanced metabolism, which is not the
case in cirrhosis. Decreased absorption is not directly related to protein binding.
Increased excretion would occur with enhanced renal function, not liver disease.
Q3. A patient is receiving a drug with a narrow therapeutic index. Which
nursing action is most important?
○ A. Administer the drug with food
○ B. Monitor serum drug levels
○ C. Increase the dose if side effects occur
○ D. Switch to a different medication
CORRECT ANSWER: B. Monitor serum drug levels
RATIONALE: A narrow therapeutic index means there is a small margin between the
therapeutic dose and the toxic dose. Close monitoring of serum drug levels is
essential to ensure the drug remains within the therapeutic range and to prevent
toxicity. Administering with food may affect absorption but does not address the
core safety concern. Increasing the dose if side effects occur is dangerous and could
precipitate toxicity. Switching medications is not indicated without clinical
justification.
Q4. A patient is prescribed a medication that is an agonist at beta-2 receptors.
Which effect would the PN expect?
○ A. Bronchoconstriction
○ B. Bronchodilation
,○ C. Increased heart rate
○ D. Decreased blood pressure
CORRECT ANSWER: B. Bronchodilation
RATIONALE: Beta-2 receptor stimulation causes smooth muscle relaxation,
particularly in the bronchial tree, resulting in bronchodilation. This is the therapeutic
effect of medications like albuterol. Bronchoconstriction would occur with beta-2
blockade. Increased heart rate is a beta-1 effect. Decreased blood pressure is not a
direct beta-2 effect.
Q5. A patient is prescribed a medication that is a competitive antagonist at H2
receptors. Which effect would the PN expect?
○ A. Decreased gastric acid secretion
○ B. Increased gastric acid secretion
○ C. Decreased histamine release
○ D. Increased histamine release
CORRECT ANSWER: A. Decreased gastric acid secretion
RATIONALE: H2 receptor antagonists (e.g., famotidine, ranitidine) block histamine at
H2 receptors on gastric parietal cells, reducing gastric acid secretion. This is the
therapeutic effect for peptic ulcer disease and GERD. Increased gastric acid secretion
would occur with H2 receptor agonists. Decreased histamine release is an effect of
mast cell stabilizers, not H2 antagonists. Increased histamine release is not a
therapeutic effect.
Q6. A patient is prescribed a medication that is a prodrug. Which statement
accurately describes a prodrug?
○ A. The drug is active in its administered form
○ B. The drug must be metabolized to become active
○ C. The drug is excreted unchanged
○ D. The drug is inactive and cannot become active
CORRECT ANSWER: B. The drug must be metabolized to become active
, RATIONALE: A prodrug is a pharmacologically inactive compound that is
metabolized in the body to an active metabolite. This design can improve
bioavailability, reduce side effects, or target specific tissues. The drug is not active in
its administered form. Prodrugs are not excreted unchanged; they are metabolized to
active forms. Prodrugs can become active through metabolism.
Q7. A patient with renal impairment is prescribed a medication that is primarily
excreted by the kidneys. What adjustment should the PN anticipate?
○ A. Increased dose
○ B. Decreased dose
○ C. No dose adjustment needed
○ D. Increased frequency of administration
CORRECT ANSWER: B. Decreased dose
RATIONALE: Renal impairment reduces drug excretion, leading to drug
accumulation and increased risk of toxicity. Dose reduction is typically required to
maintain therapeutic levels while preventing toxicity. Increased dose would worsen
accumulation. No dose adjustment is not appropriate when renal function is
compromised. Increased frequency would also worsen accumulation.
Q8. A patient is prescribed a medication that is a strong CYP3A4 inhibitor.
Which effect would this have on co-administered drugs metabolized by
CYP3A4?
○ A. Decreased drug levels
○ B. Increased drug levels
○ C. No effect on drug levels
○ D. Increased drug excretion
CORRECT ANSWER: B. Increased drug levels
RATIONALE: CYP3A4 is a major drug-metabolizing enzyme. Strong inhibitors (e.g.,
ketoconazole, clarithromycin) reduce the metabolism of co-administered drugs that
are substrates of CYP3A4, leading to increased serum levels and increased risk of
toxicity. Decreased drug levels would occur with CYP3A4 inducers. No effect is
incorrect because inhibitors alter metabolism. Increased excretion is not directly
related to CYP inhibition.
2026/2027 370 Q&As WITH NGN & RATIONALES
Practical Nursing Pharmacology Verified | 2026/2027 ATI PN
Pharmacology Curriculum Next Generation NCLEX-PN (NGN)
Standards
Domain: Pharmacokinetics & Pharmacodynamics
Q1. A patient takes an oral medication that undergoes extensive first-pass
metabolism. Which route of administration would bypass the first-pass effect
and increase bioavailability?
○ A. Sublingual
○ B. Oral sustained-release
○ C. Rectal suppository
○ D. Enteric-coated oral
CORRECT ANSWER: A. Sublingual
RATIONALE: The first-pass effect occurs when a drug is absorbed from the GI tract
and passes through the liver before reaching systemic circulation, significantly
reducing bioavailability. Sublingual administration allows the drug to be absorbed
directly into the systemic circulation through the rich vascular supply under the
tongue, completely bypassing hepatic first-pass metabolism. This results in higher
bioavailability compared to oral routes for drugs that undergo extensive first-pass
metabolism. Oral sustained-release formulations still pass through the liver via the
portal circulation and are subject to first-pass metabolism. Rectal suppositories
partially bypass the first-pass effect but a significant portion of the drug still drains
into the portal circulation via the inferior and middle hemorrhoidal veins. Enteric-
coated oral medications are designed to dissolve in the intestine but still undergo
first-pass metabolism once absorbed.
Q2. A patient with liver cirrhosis is prescribed a medication that is highly
protein-bound. Which pharmacokinetic change should the PN anticipate?
,○ A. Decreased drug half-life
○ B. Increased free drug concentration
○ C. Decreased drug absorption
○ D. Increased drug excretion
CORRECT ANSWER: B. Increased free drug concentration
RATIONALE: Liver cirrhosis reduces albumin production, leading to decreased
protein-binding capacity. With fewer protein-binding sites available, a greater
fraction of the drug remains unbound (free) in the circulation. The free fraction is
pharmacologically active and can lead to increased therapeutic effects or toxicity.
Decreased drug half-life would occur with enhanced metabolism, which is not the
case in cirrhosis. Decreased absorption is not directly related to protein binding.
Increased excretion would occur with enhanced renal function, not liver disease.
Q3. A patient is receiving a drug with a narrow therapeutic index. Which
nursing action is most important?
○ A. Administer the drug with food
○ B. Monitor serum drug levels
○ C. Increase the dose if side effects occur
○ D. Switch to a different medication
CORRECT ANSWER: B. Monitor serum drug levels
RATIONALE: A narrow therapeutic index means there is a small margin between the
therapeutic dose and the toxic dose. Close monitoring of serum drug levels is
essential to ensure the drug remains within the therapeutic range and to prevent
toxicity. Administering with food may affect absorption but does not address the
core safety concern. Increasing the dose if side effects occur is dangerous and could
precipitate toxicity. Switching medications is not indicated without clinical
justification.
Q4. A patient is prescribed a medication that is an agonist at beta-2 receptors.
Which effect would the PN expect?
○ A. Bronchoconstriction
○ B. Bronchodilation
,○ C. Increased heart rate
○ D. Decreased blood pressure
CORRECT ANSWER: B. Bronchodilation
RATIONALE: Beta-2 receptor stimulation causes smooth muscle relaxation,
particularly in the bronchial tree, resulting in bronchodilation. This is the therapeutic
effect of medications like albuterol. Bronchoconstriction would occur with beta-2
blockade. Increased heart rate is a beta-1 effect. Decreased blood pressure is not a
direct beta-2 effect.
Q5. A patient is prescribed a medication that is a competitive antagonist at H2
receptors. Which effect would the PN expect?
○ A. Decreased gastric acid secretion
○ B. Increased gastric acid secretion
○ C. Decreased histamine release
○ D. Increased histamine release
CORRECT ANSWER: A. Decreased gastric acid secretion
RATIONALE: H2 receptor antagonists (e.g., famotidine, ranitidine) block histamine at
H2 receptors on gastric parietal cells, reducing gastric acid secretion. This is the
therapeutic effect for peptic ulcer disease and GERD. Increased gastric acid secretion
would occur with H2 receptor agonists. Decreased histamine release is an effect of
mast cell stabilizers, not H2 antagonists. Increased histamine release is not a
therapeutic effect.
Q6. A patient is prescribed a medication that is a prodrug. Which statement
accurately describes a prodrug?
○ A. The drug is active in its administered form
○ B. The drug must be metabolized to become active
○ C. The drug is excreted unchanged
○ D. The drug is inactive and cannot become active
CORRECT ANSWER: B. The drug must be metabolized to become active
, RATIONALE: A prodrug is a pharmacologically inactive compound that is
metabolized in the body to an active metabolite. This design can improve
bioavailability, reduce side effects, or target specific tissues. The drug is not active in
its administered form. Prodrugs are not excreted unchanged; they are metabolized to
active forms. Prodrugs can become active through metabolism.
Q7. A patient with renal impairment is prescribed a medication that is primarily
excreted by the kidneys. What adjustment should the PN anticipate?
○ A. Increased dose
○ B. Decreased dose
○ C. No dose adjustment needed
○ D. Increased frequency of administration
CORRECT ANSWER: B. Decreased dose
RATIONALE: Renal impairment reduces drug excretion, leading to drug
accumulation and increased risk of toxicity. Dose reduction is typically required to
maintain therapeutic levels while preventing toxicity. Increased dose would worsen
accumulation. No dose adjustment is not appropriate when renal function is
compromised. Increased frequency would also worsen accumulation.
Q8. A patient is prescribed a medication that is a strong CYP3A4 inhibitor.
Which effect would this have on co-administered drugs metabolized by
CYP3A4?
○ A. Decreased drug levels
○ B. Increased drug levels
○ C. No effect on drug levels
○ D. Increased drug excretion
CORRECT ANSWER: B. Increased drug levels
RATIONALE: CYP3A4 is a major drug-metabolizing enzyme. Strong inhibitors (e.g.,
ketoconazole, clarithromycin) reduce the metabolism of co-administered drugs that
are substrates of CYP3A4, leading to increased serum levels and increased risk of
toxicity. Decreased drug levels would occur with CYP3A4 inducers. No effect is
incorrect because inhibitors alter metabolism. Increased excretion is not directly
related to CYP inhibition.
